We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Promega Designs Luciferase Reporter Assay for Drug Screening

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Promega Designs Luciferase Reporter Assay for Drug Screening"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Promega Corporation offers ONE-Glo™ Luciferase Assay Reagent, based on a completely luciferin analogue, that exhibits reproducibility with fewer false positives while generating an extended bright light signal.

The ONE-Glo Luciferase Assay Reagent is based on a luciferase substrate, developed by Promega scientists, that renders the reagent more tolerant to different sample and reaction components.

According to Promega, ONE-Glo exhibits reduced influence from luciferase inhibitors thereby resulting in fewer false positive readings, especially critical in screening applications. The percentage of likely drug compounds can be pursued and better prioritized, further reducing screening bottlenecks.

The reagent is also optimized for batch and continuous-process handling. The extended bright light output of ONE-Glo allows for high sensitivity, especially when extended incubation is required prior to reading results. Enhanced stability at room temperature and larger package sizes for screening experiments means scientists can focus more effort on running assays and less on reagent preparation.